Want to see FR:ABNX full AI Analyst Report?
ABNX Stock Chart & Stats
€1.95
€0.05(2.67%)
At close: 4:00 PM EDT
€1.95
€0.05(2.67%)
Day’s Range― - ―
52-Week Range€1.49 - €5.21
Previous CloseN/A
Volume53.48K
Average Volume (3M)284.77K
Market Cap
€78.58M
Enterprise Value€92.33M
Total Cash (Recent Filing)€3.52M
Total Debt (Recent Filing)€3.81M
Price to Earnings (P/E)―
Beta-0.39
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding42,568,070
10 Day Avg. Volume172,880
30 Day Avg. Volume284,772
Financial Highlights & Ratios
PEG Ratio-1.03
Price to Book (P/B)31.58
Price to Sales (P/S)33.12
P/FCF Ratio-42.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.46
Revenue Forecast (FY)€4.66M
Bulls Say, Bears Say
Bulls Say
Focused R&D PipelineABIONYX’s clear, specialized focus on apoA‑I biology and clinical-stage drug candidates supports durable competitive advantage in a defined therapeutic niche (inflammation, sepsis). A concentrated pipeline reduces strategic dispersion and preserves R&D expertise, aiding long-term trial progress and partnerability.
Operating Cash Burn ImprovementA reduction in operating cash outflows versus the prior year indicates management traction on cost or operational efficiency. That trend, if sustained, extends runway and reduces near-term financing pressure, giving more time for clinical milestones that underpin long-term value creation.
Positive Equity BufferMaintaining positive shareholders' equity provides a solvency buffer to absorb continued losses and fund near-term development. This retained equity base supports credibility with potential partners and lenders, improving options for non-dilutive collaborations or structured financing over the medium term.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow requires ongoing external funding to sustain development. Over time this increases dilution risk or leverage, constrains strategic flexibility, and can force prioritization or delay of clinical programs absent a clear revenue or partnership inflection.
Weak Profitability And MarginsVery large negative EBIT margins reflect a cost structure dominated by development expenses and limited revenue scaling. Without durable margin improvement or meaningful revenue, profitability is unlikely for the foreseeable term, undermining internal funding and increasing dependence on external capital.
Declining & Volatile RevenueSmall, volatile and declining revenues provide limited internal funding for R&D and fail to validate commercial traction. This volatility raises execution risk for scaling programs, weakens negotiating leverage with partners, and lengthens the timeline to sustainable operating performance.
ABIONYX Pharma SA News
ABNX FAQ
What was ABIONYX Pharma SA’s price range in the past 12 months?
ABIONYX Pharma SA lowest stock price was €1.49 and its highest was €5.21 in the past 12 months.
What is ABIONYX Pharma SA’s market cap?
ABIONYX Pharma SA’s market cap is €78.58M.
When is ABIONYX Pharma SA’s upcoming earnings report date?
ABIONYX Pharma SA’s upcoming earnings report date is Sep 24, 2026 which is in 49 days.
How were ABIONYX Pharma SA’s earnings last quarter?
ABIONYX Pharma SA released its earnings results on Mar 12, 2026. The company reported -€0.091 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.091.
Is ABIONYX Pharma SA overvalued?
According to Wall Street analysts ABIONYX Pharma SA’s price is currently Overvalued.
Does ABIONYX Pharma SA pay dividends?
ABIONYX Pharma SA does not currently pay dividends.
What is ABIONYX Pharma SA’s EPS estimate?
ABIONYX Pharma SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ABIONYX Pharma SA have?
ABIONYX Pharma SA has 42,568,070 shares outstanding.
What happened to ABIONYX Pharma SA’s price movement after its last earnings report?
ABIONYX Pharma SA reported an EPS of -€0.091 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.455%.
Which hedge fund is a major shareholder of ABIONYX Pharma SA?
Currently, no hedge funds are holding shares in FR:ABNX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ABIONYX Pharma SA
ABIONYX Pharma SA is a biotechnology company dedicated to the identification and advancement of therapies for conditions affecting the kidneys and eyes. The firm's pipeline includes CER-001, an innovative negatively-charged lipoprotein particle. This compound is designed to mimic the structural and functional attributes of pre-beta HDL, utilizing human recombinant apoA-I (a natural high-density lipoprotein protein) along with natural phospholipids like sphingomyelin and dipalmitoylphosphatidylglycerol. CER-001 is currently under development for patients recovering from acute coronary syndrome and those with familial primary hypoalphalipoproteinemia. Another key candidate, CER-002, is a specific agonist for peroxisome proliferator-activated receptor delta, targeting cardiovascular and metabolic diseases. Additionally, CER-209 is being developed as a potential treatment for metabolic liver diseases, atherosclerosis, and non-alcoholic steatohepatitis (NASH). ABIONYX maintains strategic partnerships with GTP Biologics and VBI Therapeutics Group for the bioproduction of its bio-HDL in France. Established in 2005, the company operated as Cerenis Therapeutics Holding SA before its rebranding to ABIONYX Pharma SA in August 2019. Its operations are headquartered in Balma, France.